app_store_button

google_play_button

DK - Details page - Device banner - 894x1036

Nyd den ubegrænsede adgang til tusindvis af spændende e- og lydbøger - helt gratis

Lyt når som helst, hvor som helst 

Medscape

This podcast delivers Dr. John Mandrola's summary and perspective on top news of the week that cardiologists can't miss. This podcast is intended for US health professionals only.

This Week in Cardiology

Beta-blocker in non-obstructive hypertrophic cardiomyopathy, a head-to-head apixaban vs rivaroxaban RCT, diltiazem vs metoprolol combined with DOAC, and the accuracy of smart watches for AF are the topics John Mandrola, MD, discusses in this week's podcast.
 
This podcast is intended for healthcare professionals only.
 
To read a partial transcript or to comment, visit:
 
https://www.medscape.com/twic
 
I Listener Feedback
 
 EMPATICC trial https://academic.oup.com/eurheartj/article/47/9/1034/8242490 
II Beta-blocker in Non-obstructive HCM
 
 BB vs Calcium Channel Blocker in Non-obstructive HCM https://doi.org/10.1016/j.jacc.2025.11.028 RCT of Metoprolol in Patients With Obstructive HCM https://doi.org/10.1016/j.jacc.2021.07.065 
III Apixaban vs Rivaroxaban for Bleeding Risk
 
 COBRRA Trial https://www.nejm.org/doi/full/10.1056/NEJMoa2510703 AMPLIFY Trial (Apixaban) https://www.nejm.org/doi/10.1056/NEJMoa1302507 EINSTEIN Trial (Rivaroxaban) https://www.nejm.org/doi/full/10.1056/NEJMoa1007903 
IV Diltiazem vs Metoprolol When Combined with DOAC
 
 Risk for Bleeding in AF Patients Using Apixaban or Rivaroxaban With Diltiazem https://www.acpjournals.org/doi/10.7326/ANNALS-25-01408 
V Actual Clinical Use of Smart Watches
 
 CIRCA-DOSE Original Trial https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.119.042622 Wearable Smartwatches for AF Detection After Ablation https://doi.org/10.1093/europace/euaf280 
You may also like:
 
The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
 
Questions or feedback, please contact news@medscape.net

Mar 13 2026 This Week in Cardiology

Listener feedback, urgent AF ablation, AF ablation as a stroke-reducing therapy, implantable loop recorder accuracy, and HF management in the setting of serious disease are the topics John Mandrola, MD, discusses in this week's podcast.
 
This podcast is intended for healthcare professionals only.
 
To read a partial transcript or to comment, visit:
 
https://www.medscape.com/twic
 
I Urgent AF ablations
 
 Urgent vs Elective AF Ablation in the US https://www.jacc.org/doi/10.1016/j.jacep.2025.12.030 
II AF Ablation Is Not Likely a Good Therapy for Stroke Reduction
 
 STABLED Trial • 
https://jamanetwork.com/journals/jamaneurology/fullarticle/2845745 Catheter Ablation for AF Associated With Lower Incidence of Stroke • 
https://doi.org/10.1093/eurheartj/ehw087 
III Loop Recorders
 
 ILR Accuracy - Multicenter, Multidevice Comparison • 
https://doi.org/10.1016/j.jacep.2025.12.039 
IV Heart Failure Therapy when there is Cancer
 
 EMPATICC Trial • 
https://doi.org/10.1093/eurheartj/ehaf705 
You may also like:
 
The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
 
Questions or feedback, please contact news@medscape.net

Mar 06 2026 This Week in Cardiology

A superb note on CPR and DNR orders, patients' vs doctors' preferences for statins, more on GLP-1s, another LAAC story, and some closing cautionary notes on PFA are the topics John Mandrola, MD, discusses in this week's podcast.
 
This podcast is intended for healthcare professionals only.
 
To read a partial transcript or to comment, visit:
 
https://www.medscape.com/twic
 
I Listener Feedback
 
 Addressing Inadequate Documentation of Unilateral DNR https://jamanetwork.com/journals/jama/fullarticle/2829203 Video: Can We Talk About CPR? https://www.youtube.com/watch?v=yTCRfY3ETvI Personal Reminiscences of CPR's Origin https://www.ajconline.org/article/S0002-9149(03)00977-9/pdf 
II Public Preferences for Statin Therapy
 
 Measuring Public Preferences for Statin Therapy • 
https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2844660 
III GLP-1 RA News
 
 ACHIEVE Trial • 
https://doi.org/10.1016/S0140-6736(26)00202-3 
IV New Trial in GLP-1 for Patients with AF
 
 Seminal-AF Trial • 
https://clinicaltrials.gov/study/NCT06499857 
V Relationship between Spontaneous Echo Contrast and LAAC Outcomes
 
 OCEAN-LAAC Trial • 
https://doi.org/10.1016/j.jacep.2025.09.028 News Release on Upcoming LAAOS-4 trial • 
https://www.phri.ca/watchman/ Reading the "Smoke" -- Editorial on OCEAN-LAAC • 
https://www.jacc.org/doi/10.1016/j.jacep.2025.10.029 
VI Concluding Remarks on My Talk at Western AF
 
 Delayed Myocardial Ischemia and Malignant Arrhythmias After PFA • 
https://www.ahajournals.org/doi/abs/10.1161/CIRCULATIONAHA.125.077983 
You may also like:
 
The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington

Feb 27 2026 This Week in Cardiology

EVOLUT Low Risk data, a provocative meta-analysis, DNR orders, targeted hypothermia, good news in HFpEF evidence, and GLP-1s as AF drugs are the topics John Mandrola, MD, discusses in this week's podcast.
 
This podcast is intended for healthcare professionals only.
 
To read a partial transcript or to comment, visit:
 
https://www.medscape.com/twic
 
I EVOLUT Low Risk 6-year Results and a 5-year Meta-Analysis of TAVR vs SAVR
 
 6-Year Outcomes of TAVR vs SAVR https://www.jacc.org/doi/10.1016/j.jacc.2026.02.5063 EVOLUT Low Risk Trial at 2 years https://www.nejm.org/doi/full/10.1056/NEJMoa1816885 EVOLUT Low Risk Trial at 3 years https://www.jacc.org/doi/10.1016/j.jacc.2023.02.017 EVOLUT Low Risk Trial at 4 years https://www.jacc.org/doi/10.1016/j.jacc.2023.09.813 Nonproportional Hazards for Time-to-Event Outcomes in Clinical Trials https://www.jacc.org/doi/10.1016/j.jacc.2019.08.1034 TAVR vs SAVR 5-Year Outcomes - Systematic Review https://heart.bmj.com/content/early/2026/02/11/heartjnl-2025-327092 TAVR vs SAVR Updated Meta-Analysis of RCTs https://www.jacc.org/doi/10.1016/j.jacc.2024.12.031 UK TAVI Trial https://jamanetwork.com/journals/jama/fullarticle/2792251 Dr David Cohen on X https://x.com/djc795/status/2023556582030852172?s=46&t=zXMCUoVjSsdyemzWlzeBjA 
II DNR in the Hospital
 
 Inadequate Documentation of Unilateral DNR Orders • 
https://jamanetwork.com/journals/jama/fullarticle/2829203 GeriPal Blog Unilateral DNR Orders • 
https://geripal.org/unilateral-dnr-gina-piscitello-erin-demartino-will-parker/ 
III Yet another failure of Targeted Hypothermia
 
 2-Year Follow-Up of TTM2 Trial • 
https://jamanetwork.com/journals/jamaneurology/fullarticle/2845193 TTM2 Trial • 
https://www.nejm.org/doi/full/10.1056/NEJMoa2100591 
IV Good news in HFpEF Evidence
 
 ALT-FLOW II Trial • 
https://doi.org/10.1093/ejhf/xuaf016 
V GLP-1 as AF drugs
 
 Semaglutide as Adjunctive Therapy in Obesity-Related PAF • 
https://doi.org/10.1093/europace/euag018 
You may also like:
 
The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
 
Questions or feedback, please contact news@medscape.net

Feb 20 2026 This Week in Cardiology

Ticagrelor vs prasugrel, a new LAAC device, pulsed field ablation AF results, lifestyle intervention in AF, the term "provider" vs "doctor," and coffee are the topics John Mandrola, MD, discusses in this week's podcast.
 
This podcast is intended for healthcare professionals only.
 
To read a partial transcript or to comment, visit:
 
https://www.medscape.com/twic
 
I TUXEDO-2 Trial
 
 TUXEDO-2 Trial https://jamanetwork.com/journals/jamacardiology/fullarticle/2844869 ISAR-REACT 5 Trial https://www.nejm.org/doi/full/10.1056/NEJMoa1908973 
II VERITAS Study of Dual-Seal LAAO
 
 VERITAS Study • 
https://doi.org/10.1016/j.jacep.2026.01.021 
III PFA vs RF over 4 years
 
 Advent-LTO study • 
https://www.nature.com/articles/s41591-026-04246-4 ADVENT Study • 
https://www.nejm.org/doi/full/10.1056/NEJMoa2307291 SPHERE PER-AF Study • 
https://www.nature.com/articles/s41591-024-03022-6
 • 
SINGLE SHOT CHAMPION Study • 
https://www.nejm.org/doi/full/10.1056/NEJMoa2502280 BEAT PAROX-AF Trial • 
https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehaf1115/8436829 
IV What's in a Name — Use of the Term "Provider"
 
 Physicians Are Not Providers: The Ethical Significance of Names • 
https://www.acpjournals.org/doi/10.7326/ANNALS-25-03852 
V Coffee and Dementia Risk
 
 Coffee/Tea Intake and Dementia Risk • 
https://jamanetwork.com/journals/jama/fullarticle/2844764 Mandrola Commentary: Enough With the Coffee Research and Other Distractions • 
https://www.medscape.com/viewarticle/883709 
VI Lifestyle interventions Post AF ablation
 
 Improving Outcomes of AF by Lifestyle Interventions • 
https://academic.oup.com/eurheartj/article/47/6/669/8243674 
You may also like:
 
The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
 
Questions or feedback, please contact news@medscape.net

Feb 13 2026 This Week in Cardiology

Problems with the PREVENT score, a breakthrough in lipid-lowering therapy, a surprising benefit in stroke care, and more thoughts on statins and preventive care of heart disease are the topics John Mandrola, MD, discusses in this week's podcast.
 
This podcast is intended for healthcare professionals only.
 
To read a partial transcript or to comment, visit:
 
https://www.medscape.com/twic
 
I PREVENT Score
 
 PREVENT Equations in Young Adults • 
https://doi.org/10.1016/j.jacc.2025.12.019 Hospital Readmission Reduction Program for HF 
 https://pmc.ncbi.nlm.nih.gov/articles/PMC7664458/
 
II A New Breakthrough in LDL-C Management With an Oral PCSK9 Inhibitor
 
 https://www.medscape.com/viewarticle/time-overcome-pcsk9i-inertia-new-data-future-options-2025a1000wf8
 
 CORALreef Trial • 
https://www.nejm.org/doi/full/10.1056/NEJMoa2511002 CORALreef Outcomes Trial • 
https://clinicaltrials.gov/study/NCT06008756 
III A Win for the Factor XI Inhibitor Asundexian – OCEANIC Stroke Trial
 
 https://www.medscape.com/viewarticle/first-clear-win-factor-xia-inhibitors-stroke-reduced-2026a10003t0
 
 OCEANIC-STROKE Slide deck • 
https://clinicaltrialresults.org/wp-content/uploads/2026/02/26-02-02_ISC_OCEANIC-STROKE-primary.pdf OCEANIC-AF Study Stopped Early • 
https://www.bayer.com/media/en-us/oceanic-af-study-stopped-early-due-to-lack-of-efficacy/ 
IV Statin Side Effects
 
 Assessment of AEs Attributed to Statins -- Meta-analysis • 
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)01578-8/fulltext N-of-1 Trial to Assess AEs of Statins • 
https://www.nejm.org/doi/full/10.1056/NEJMc2031173 When to Start a Statin Is a Decision About Preference -- Editorial • 
https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.117.029808 
V Heart Disease Statistics
 
 CV Statistics in the US, 2026 • 
https://www.jacc.org/doi/10.1016/j.jacc.2025.12.027 
You may also like:
 
The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
 
Questions or feedback, please contact news@medscape.net

Feb 06 2026 This Week in Cardiology

Listener feedback, huge news in the rapidly expanding world of PFA AF Ablation, obesity, and a beautiful trial studying an AI-enhanced diagnostic tool in the office are the topics discussed by John Mandrola, MD, in this week's podcast.
 
This podcast is intended for healthcare professionals only.
 
To read a partial transcript or to comment, visit:
 
https://www.medscape.com/twic
 
I Listener Feedback
 
 Risk-Based TEE Omission in PVI • 
10.1016/j.hrthm.2025.04.056 External Link 
II PFA News
 
 BEAT PAROX-AF trial • 
https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehaf1115/8436829 Life-Threatening Delayed Myocardial Ischemia and Malignant Arrhythmias Occurring After PFA • 
https://www.ahajournals.org/doi/full/10.1161/CIRCULATIONAHA.125.077983 Heart Rhythm TV: Life-Threatening Delayed Myocardial Ischemia and Malignant Arrhythmias https://www.youtube.com/watch?v=M-npoLKmRa4 MAUDE Adverse Event report • 
https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfmaude/detail.cfm?mdrfoi__id=23733351&pc=QZI 
III Obesity trends
 
 US State-Level Obesity Trends 1990-2022 and Forecasted to 2035 • 
https://jamanetwork.com/journals/jama/fullarticle/2844495 
IV New Tools in the Office
 
 TRICORDER Trial • 
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)02156-7/fulltext 
You may also like:
 
The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
 
Questions or feedback, please contact news@medscape.net

Jan 30 2026 This Week in Cardiology

Listener feedback, the value of procedural volume for TAVR and MTEER, ventricular arrhythmia in older athletes, and the Goldilocks time horizon for predicting and modifying CV risk are the topics John Mandrola, MD, discusses in this week's podcast.
 
This podcast is intended for healthcare professionals only.
 
To read a partial transcript or to comment, visit:
 
https://www.medscape.com/twic
 
I Procedural Volume and Outcomes for TAVI and M-TEER
 
 Operator Procedural Volumes and Outcomes for TAVR and MTEER https://jamanetwork.com/journals/jamacardiology/fullarticle/2843740 
II Ventricular Arrhythmia in Older Male Endurance Athletes
 
Myocardial Fibrosis May Raise Arrhythmia Risk in Older Male Endurance Athletes
 
 https://www.medscape.com/viewarticle/myocardial-fibrosis-may-raise-arrhythmia-risk-older-male-2026a10001y0
 
 Timing and Relationship of VA With Exercise Patterns in Older Male Endurance Athletes • 
https://doi.org/10.1093/eurjpc/zwag021 
III Predicting Cardiac Risk and Statin Use
 
 30-Year ASCVD Risk Among US Adults Aged 30-59 • 
https://www.ahajournals.org/doi/10.1161/CIRCOUTCOMES.125.012348 
You may also like:
 
The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
 
Questions or feedback, please contact news@medscape.net

Jan 23 2026 This Week in Cardiology

Some great listener feedback, one of the best studies of the year in atrial fibrillation and heart failure, imaging to exclude left atrial thrombus, and a truly amazing first cardiac procedure are the topics John Mandrola, MD, discusses in this week's podcast.
 
This podcast is intended for healthcare professionals only.
 
To read a partial transcript or to comment, visit:
 
https://www.medscape.com/twic
 
I Listener Feedback
 
On Fish Oil and AF
 
 Links between omega-3 fatty acids and AF https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.121.058596 Omega-3 and risk of AF https://doi.org/10.1016/j.pcad.2024.11.003 DHA vs EPA in reducing vulnerability to AF https://www.ahajournals.org/doi/10.1161/CIRCEP.112.971515 
II Withdrawal of HF Therapy AF rhythm control
 
The AF is Gone, the EF Is Up. Can You Stop the HF Meds?
 
 https://www.medscape.com/viewarticle/af-gone-ef-can-you-stop-hf-meds-2024a1000h6o
 
 Effect of beta-blockers in patient with HF plus AF -- meta-analysis • 
https://pubmed.ncbi.nlm.nih.gov/25193873/ TRED HF Trial • 
10.1016/S0140-6736(18)32484-X External Link WITHDRAW-AF Trial • 
https://academic.oup.com/eurheartj/article/47/2/250/8238240 
III ICE or TEE Before AF Ablation
 
 ICE vs TEE in Atrial Fibrillation Ablation • 
https://jamanetwork.com/journals/jamacardiology/fullarticle/2839370 
IV The Vector Procedure
 
 Percutaneous Aorto-Coronary Bypass Graft: the VECTOR procedure • 
https://www.ahajournals.org/doi/10.1161/CIRCINTERVENTIONS.125.016130 
You may also like:
 
The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
 
Questions or feedback, please contact news@medscape.net

Jan 16, 2026 This Week in Cardiology

The limits of knowing coronary artery disease anatomy, fish oil and AF risk, a new drug for PSVT, and maybe I was wrong about a drug for AF conversion (the RAFF4 trial). These are the topics John Mandrola, MD, discusses in this week's podcast.
 
This podcast is intended for healthcare professionals only.
 
To read a partial transcript or to comment, visit:
 
https://www.medscape.com/twic
 
I Prediction of CAD is hard — even if you have anatomy
 
 CCTA in Prediction of First Coronary Events https://jamanetwork.com/journals/jama/fullarticle/2841255 
II Fish Oil and AF (and as a bonus we learn again about analytic flexibility)
 
 Are Fish Oils on the Hook for AF Risk? 
https://www.medscape.com/viewarticle/995290
 
 Omega-3 and Fish Oil Use With Risk of AF • 
https://www.ahajournals.org/doi/full/10.1161/JAHA.125.043031 Effect of Long-Term Marine Omega-3 Fatty Acids on the Risk of AF • 
https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.121.055654 RESPECT-EPA Trial • 
https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.123.065520 Association Between Omega-3 Fatty Acids and AF: Meta Analysis • 
https://link.springer.com/article/10.1007/s10557-021-07204-z Fish Oil Supplements and Risk of AF • 
https://academic.oup.com/eurjpc/article/29/14/1911/6679610 Editorial: Fish Oil Supplements and AF Risk • 
https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.121.057464 
III A New Drug for PSVT
 
 FDA Approval • 
https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-drug-type-abnormally-fast-heart-rhythm RAPID trial • 
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(23)00776-6/fulltext 
IV AF Conversion with Vernakalant
 
 RAFF4 Trial • 
https://www.bmj.com/content/391/bmj-2025-085632.long Editorial: Rapid Cardioversion for Acute AF • 
https://www.bmj.com/content/391/bmj.r2264 
VI A Quick Note on HFpEF
 
Med Op-Ed: Avalanche Survival, HFpEF Skepticism, and More
 
 https://www.medscape.com/viewarticle/med-op-ed-avalanche-survival-hfpef-skepticism-and-more-2026a1000012
 
You may also like:
 
The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
 
Questions or feedback, please contact news@medscape.net

Jan 09 2026 This Week in Cardiology

COVID, tocilizumab, hypertrophic cardiomyopathy, cerebral microbleeds, and surrogate endpoints are the topics discussed by John Mandrola, MD, in this week's podcast

Oct 23, 2020 This Week in Cardiology Podcast

Lyt når som helst, hvor som helst

Other podcasts you might like ...